Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.

Giusti, Massimo; Gussoni, Gualberto; Cuttica, Carla Micaela; Giordano, G

doi:10.1210/jcem.81.6.8964833

Cited by 68 publications

(40 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In agreement with other trials with lanreotide SR (16,22,25), we observed a small rise in fasting blood glucose during therapy, whereas others found no change in glucose metabolism (23). In our study, as well as in others (22,23), no obvious deterioration in glucose metabolism was seen in patients with overt diabetes.…”

Section: Discussionsupporting

confidence: 93%

“…In our study, as well as in others (22,23), no obvious deterioration in glucose metabolism was seen in patients with overt diabetes.…”

Section: Discussionsupporting

confidence: 82%

“…The evaluation of success rate for GH levels between the different studies is even more dif®cult as differences in normality vary between 2.5 and 5 mg/l. In addition, many patients with a GH level below 2.5 mg/l during therapy continue to have an elevated IGF-I and vice versa (22).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients

Verhelst

Pedroncelli²,

Abs³

et al. 2000

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Slow-release (SR) lanreotide is a long-acting somatostatin analog that has been developed in order to overcome the inconvenience of multiple daily subcutaneous injections of octreotide, required for metabolic control in acromegaly. Lanreotide SR has been found to be well tolerated and effective in reducing GH and IGF-I levels but clinical data are still limited compared with those with subcutaneous octreotide treatment. Design: Sixty-six unselected patients with active acromegaly were therefore evaluated in a multi-center, prospective, open label study. Lanreotide SR was given at a dose of 30 mg intramuscular every 7±14 days. Methods: At baseline and after 2, 4, 8, 12, 24, 36 and 48 weeks patients underwent a clinical examination with assessment of acromegaly related symptoms, and blood was sampled for serum GH, IGF-I, prolactin, glycosylated hemoglobin, fasting glucose, hematology, kidney function and liver function tests. Biliary ultrasonography and pituitary magnetic resonance imaging were performed at baseline and after one year.

show abstract

Section: Discussionsupporting

confidence: 93%

“…In our study, as well as in others (22,23), no obvious deterioration in glucose metabolism was seen in patients with overt diabetes.…”

Section: Discussionsupporting

confidence: 82%

See 1 more Smart Citation

Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients

Verhelst

Pedroncelli²,

Abs³

et al. 2000

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Since the baseline IGF-I status did not influence the outcome of mean GH levels, we suggest that L-Autogel treatment can control clinical symptoms of acromegaly irrespective of GH levels. This has indeed been previously reported for lanreotide SR (8,35) and for octreotide LAR (23,24). Interpretation of our data is, however, limited by the nature of our open, one-way protocol.…”

Section: Discussionsupporting

confidence: 85%

Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR

Alexopoulou¹,

Abrams

Verhelst

et al. 2004

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: This open label, multicentre study was designed to evaluate the efficacy and tolerability of lanreotide Autogel (L-Autogel) in acromegalic patients over a 24-week period. The outcome of treatment with this new, long-acting, aqueous formulation of lanreotide was also compared with the patients' previous treatment with octreotide long acting repeatable (LAR). Design and methods: Twenty-five acromegalic patients (13 males, mean age 51^12 years) were switched from octreotide LAR (20-40 mg/4 weeks for at least 6 months) to L-Autogel, given deep subcutaneously at a fixed dose of 90 mg/4 weeks. After 12 weeks, the dose of L-Autogel was titrated according to patients' mean GH and IGF-I levels at week 8. It was increased to 120 mg/4 weeks if GH . 2.5 mg/l or if IGF-I was above the age-adjusted normal range. It was reduced to 60 mg/4 weeks if mean GH , 1 mg/l and IGF-I was within the normal range. If the values did not fall within these ranges, the dose remained unchanged at 90 mg. Results: After 24 weeks of treatment with L-Autogel (final doses 60 mg in 3 patients, 90 mg in 4 patients and 120 mg in 18 patients), mean serum GH (2.9^2.4 mg/l) and IGF-I concentrations (332^193 mg/l) remained statistically unchanged when compared with baseline values under octreotide LAR (GH 2.4^1.8 mg/l and IGF-I 337^201 mg/l, non significant (NS)). There was a significant improvement of the acromegalic symptom score over the study period, from 4.8^3.4 to 2.8^2.5 (P , 0.001) and a small but significant reduction in the residual pituitary tumour volume (P , 0.05). Local side-effects were observed less frequently and no technical problems were encountered with the L-Autogel injections, as opposed to treatment with octreotide LAR (60 difficult injections/150 (P , 0.001)). Conclusions: L-Autogel appears to be as effective as octreotide LAR in lowering GH and IGF-I concentrations in acromegalic patients. This treatment was also well tolerated by the patients, giving fewer local side-effects and technical problems with injections. These advantages may improve the long-term acceptability of medical treatment in acromegaly.

show abstract

“…a Frequencies are adopted from: octreotide LAR: http://www.rxlist.com according to manufacturer reports Cozzi et al, 2003;Davies et al, 1998;Flogstad et al, 1997;Jallad et al, 2005;Lancranjan and Atkinson, 1999;Lancranjan et al, 1996;Stewart et al, 1995); lanreotide autogel: Caron et al, 2002Caron et al, , 2006Lucas and Astorga, 2006); lanreotide SR: Attanasio et al, 2003;Caron et al, 1997;Chanson et al, 2000a,b;Giusti et al, 1996;Gutt et al, 2005;Lucas et al, 2003;Marek et al, 1994;Morange et al, 1994;Verhelst et al, 2000).…”

mentioning

confidence: 99%

Somatostatin agonists for treatment of acromegaly

Ben-Shlomo

Melmed

2008

Molecular and Cellular Endocrinology

View full text Add to dashboard Cite

The discovery of somatotropin-release inhibitory factor (SRIF) in hypothalamic extract in 1970 led to the synthesis of the first somatostatin analog octreotide, discovery of five somatostatin receptor subtypes, and development of additional somatostatin receptor ligands (SRL) as pharmacotherapy for acromegaly and other neuroendocrine tumors. Long-acting formulations of SRL (octreotide LAR Depot, lanreotide SR and lanreotide autogel) assure improved patient compliance with weekly up to monthly injections, and are commonly used as primary or adjuvant treatment of acromegaly. We review SRL currently available, emphasizing long-acting compounds and their efficacy in controlling acromegaly. Disease control is evaluated by biochemical markers, tumor shrinkage, and diseasesymptom improvement balanced against drug-related side effects.

show abstract

Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.

Cited by 68 publications

References 41 publications

Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients

Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients

Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR

Somatostatin agonists for treatment of acromegaly

Contact Info

Product

Resources

About